Local Gene Delivery and Methods to Control Immune Responses in Muscles of Normal and Dystrophic Dogs

Methods in Molecular Biology

Volumn 709, Issue , 2011, Pages 265-275

  Wang, Zejing ^a   Tapscott, Stephen J ^a,b   Storb, Rainer ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

AAV; Adeno associated virus; ATG; Cellular immunity; CSP; cxmd; DMD; Dog; Duchenne muscular dystrophy; Immunosuppression; MMF; Muscle

Indexed keywords

ANTIBODY; CAPSID PROTEIN; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADENO ASSOCIATED VIRUS; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; ARTICLE; CELLULAR IMMUNITY; DOG; GENE THERAPY; GENE TRANSFER; GENETICS; IMMUNOLOGY; SKELETAL MUSCLE;

ANIMALS; ANTIBODIES; CAPSID PROTEINS; CYCLOSPORINE; DEPENDOVIRUS; DOGS; GENE THERAPY; GENE TRANSFER TECHNIQUES; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYCOPHENOLIC ACID;

EID: 79960054903     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61737-982-6_17     Document Type: Chapter

References (29)

1. Finsterer J, Stollberger C (2003) The heart in human dystrophinopathies Cardiol 99, 1–19.
2. Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes (Review). Lancet Neurol 2, 731–740.
3. Tyler KL (2003) Origins and early descriptions of “Duchenne muscular dystrophy”. Muscle Nerve 28, 402–422.
4. Foidart M, Foidart JM, Engel WK (1981) Collagen localization in normal and fibrotic human skeletal muscle. Arch Neurol 38, 152–157.
5. Duan D (2006) Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 15 (Spec. No. 2), R253–R261.
6. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12, 787–789.
7. Wang Z, Chamberlain JS, Tapscott SJ, Storb R (2009) Gene therapy in large animal models of muscular dystrophy. ILAR J 50, 187–198.
8. Athanasopoulos T, Fabb S, Dickson G (2000) Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases. Int J Mol Med 6, 363-375.
9. Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A, et al. (2005) Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 11, 57–65.
10. Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN, et al. (2008) A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16, 1944–1952.
11. Athanasopoulos T, Graham IR, Foster H, Dickson G (2004) Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11 Suppl 1, S109–S121.
12. Warrington KH, Jr., Herzog RW (2006) Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119, 571–603.
13. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, et al. (2007) Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18, 18–26.
14. Sabatino DE, Mingozzi F, Hui DJ, Chen H, Colosi P, Ertl HC, et al. (2005) Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 12, 1023–1033.
15. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, et al. (2006) Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13, 77–87.
16. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response (erratum appears in Nat Med 12, 592). Nat Med 12, 342-347.
17. Maris M, Storb R (2003) The transplantation of hematopoietic stem cells after non-myeloablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 28, 13-24.
18. Kirk AD (2003) Crossing the bridge: large animal models in translational transplantation research. Immunol Rev 196, 176–196.
19. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immu-nosuppression after marrow transplantation. Blood 89, 3048–3054.
20. Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, et al. (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91, 2581–2587.
21. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390–3400.
22. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloabla-tive conditioning for patients with hematologic malignancies. Blood 102, 2021–2030.
23. Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb H-J, Lerner KG, et al. (1974) Effect of prior blood transfusions on marrow grafts: Abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 112, 1508–1516.
24. Buckley JD, Chard RL, Baehner RL, Nesbit ME, Lampkin BC, Woods WG, et al. (1989) Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer 63, 1457–1465.
25. Storb R, Kolb HJ, Graham TC, Kolb H, Weiden PL, Thomas ED (1973) Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 42, 601–609.
26. Storb R, Gluckman E, Thomas ED, Buckner CD, Clift RA, Fefer A, et al. (1974) Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 44, 57–75.
27. Doney K, Leisenring W, Storb R, Appelbaum FR, for the Seattle Bone Marrow Transplant Team (1997) Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 126, 107–115.
28. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, et al. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosup-pression. Mol Ther 15, 1160–1166.
29. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, et al. (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4, 1251–1258.